Background--Clinical studies implicate trimethylamine N-oxide (TMAO; a gut microbiota-dependent nutrient metabolite) in cardiovascular disease risk. There is a lack of population-based data on the role of TMAO in advancing early atherosclerotic disease. We tested the prospective associations between TMAO and coronary artery calcium (CAC) and carotid intima-media thickness (cIMT).
R ecent studies implicate trimethylamine N-oxide (TMAO; a gut microbiota-dependent nutrient metabolite) in advancing cardiovascular disease (CVD) risk. [1] [2] [3] In the apoE À/À mouse, direct TMAO administration resulted in increased foam cell formation, decreased reverse cholesterol transport, and progression of aortic plaque lesions. 1, 3 In a large sample of patients undergoing elective coronary angiography, plasma TMAO concentrations were positively associated with the rate of major CVD events over a 3-year follow-up. 2 Production of TMAO from dietary precursors relies, in part, on gut bacteria, and atherosclerosis susceptibility has been transferred through gut microbial transplantation in a mouse model. 4 These findings have generated interest given that they may point to an important new prognostic variable that is potentially modifiable through targeted diet or gut microbial interventions. Although animal models indicate that TMAO influences CVD risk through atherosclerosis, there have been no prospective studies of early atherosclerosis progression in population-based samples. Previous human studies of TMAO and atherosclerosis have been small or cross-sectional and have yielded mixed results. 5, 6 Studies of TMAO and CVD events have been conducted in older clinic-based samples with a high prevalence of comorbidities, 1, 6 and the relationship between TMAO and atherosclerotic disease in younger and healthier individuals is not known. Furthermore, previous data indicate that significantly increased CVD risk may be restricted to higher concentrations of TMAO. 2 TMAO has been shown to increase with age, 2 and there is a need to understand the relevance of lower TMAO concentrations that are typical among younger individuals. We tested the hypothesis that plasma TMAO is positively associated with CAC incidence and progression using data from CARDIA (Coronary Artery Risk Development in Young Adults), a prospective, population-based cohort study of CVD risk evolution in adulthood. Coronary artery calcium (CAC) is a measure of atherosclerosis in the coronary arteries 7 and is predictive of fatal and nonfatal coronary heart disease and CVD events. 8 In a study of 4 racial/ethnic groups, participants with a CAC score between 1 and 100 had a hazard rate of major coronary events of 3.89, and those with a score between 101 and 300 had a hazard rate of 7.08, as compared to individuals with a CAC score of 0. 8 CAC accelerates in early-middle adulthood, 9 before many comorbidities become prevalent in the general population. We measured TMAO and quantified prospective associations between TMAO and 10-year (1) CAC incidence and (2) CAC progression. Our analysis tests the role of TMAO in the advancement of atherosclerosis in a population-based sample of adults at a critical life period for CVD prevention.
Materials and Methods

Study Sample
CARDIA, a longitudinal study of cardiometabolic disease risk over adulthood, began in 1985-1986 with 5115 black and white adults aged 18 to 30 years recruited from 4 metropolitan areas (Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA). 10 There have been 7 follow-up examinations (years 2, 5, 7, 10, 15, 20, and 25) with the majority of survivors participating (91%, 86%, 81%, 79%, 74%, 72%, and 72%, respectively). CARDIA was approved by institutional review boards of each field center; each study participant provided informed written consent. 
TMAO Measurement
Participants were asked to fast ≥12 hours and avoid heavy physical activity and smoking for the 2 hours before the exam. Blood was drawn by venipuncture and stored at 4°C. Within 90 minutes of collection, blood samples were separated through centrifugation, aliquoted into airtight vials, flash-frozen, and stored at À70°C.
TMAO was quantified using liquid chromatography/stableisotope dilution/multiple-reaction monitoring/mass spectrometry by the University of North Carolina Nutrition Obesity Research Center. 
Other Measurements
Standard questionnaires were used to obtain demographic (age, sex, race, and education) and behavioral (physical activity, cigarette smoking, and alcohol consumption) data. The validated interview-administered CARDIA Physical Activity History queried past-year engagement in 13 activities, from which a total activity score was calculated. 15 Participants reported their medication use for hypertension, lipid lowering, and diabetes mellitus. Diet was assessed with an intervieweradministered, validated dietary history in 1985-1986, 1992-1993, and 2005-2006 . 16 Standardized protocols were used by trained staff for all clinic measures. Height and weight were measured to the nearest 0.50 cm and 0.20 kg, respectively, for body mass index (BMI; kg/m 2 ). Resting systolic and diastolic blood pressure values were calculated as the mean of the second and third of 3 measurements taken with a random-zero sphygmomanometer. Plasma concentrations of total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides were determined using enzymatic procedures or estimated by the Friedewald equation. Serum glucose was measured using hexokinase coupled to glucose-6-phosphate dehydrogenase. Insulin was measured with the use of a radioimmunoassay. Diabetes mellitus was defined as having fasting glucose level ≥126 mg/dL (7 mmol/L), 2-hour oral glucose tolerance test (OGTT) ≥200 mg/dL (11.1 mmol/L), glycated hemoglobin (HbA1c) ≥6.5% (48 mmol/mol), or use of hypoglycemic medications. Plasma C-reactive protein (CRP) was measured using high-sensitivity, nephelometry-based methods, soluble intracellular adhesion molecule 1 (sICAM-1) by enzyme-linked immunosorbent assay, and F 2 -isoprostanes by gas chromatography/mass spectrometry. Urine albumin was measured using a nephelometric procedure with a specific antialbumin monoclonal antibody and creatinine using the Jaffe method. Carotid intima-media thickness (cIMT) was assessed in 2005-2006 from high-resolution B-mode ultrasound images at 3 levels: common carotid artery, carotid artery bulb, and internal carotid artery. We used the average maximum common cIMT (4 measurements) in analysis.
Statistical Analysis
Educational status was modeled as the maximum (at any visit) reported years completed. Smoking was classified as current versus former/never. To account for typical dietary consumption, we averaged consumption of TMAO precursor food groups, including eggs and red meat, from years 7 (1992-1993) and 20 (2005-2006) of CARDIA, as well as a measure of diet quality. 17 We natural log-transformed CRP and triglycerides to normalize data. Estimated glomerular filtration rate (eGFR) (mL/min per 1.73 m 2 ) was calculated from serum creatinine using the 2009 CKD-EPI (CKD Epidemiology Collaboration) equation. 18 Urine albumin-creatinine ratios (UACRs) were standardized to sex and race and expressed in milligrams per gram of creatinine. We estimated insulin resistance using homeostasis model assessment for insulin resistance (HOMA-IR). included years of education, current cigarette smoking (current, never/former), intensity units of physical activity, systolic blood pressure, LDL-C, HDL-C, natural log-transformed triglycerides, HOMA-IR, BMI, natural log-transformed high-sensitivity CRP, eGFR, and UACR. We tested the sensitivity of models additionally adjusted for the use of lipid-lowering or blood pressure mediation, sICAM-1 and F 2 -isoprostanes, and dietary variables.
Incident CAC was defined as having an Agatston score of 0 in 2000-2001 (Year 15) and a score >0 at follow-up. We used Poisson regression with an offset of time to incident CAC to estimate the effect of TMAO on 10-year CAC incidence. To account for CT error in detection of CAC, we reran models based on a ≥10 score increase. We also defined 10-year CAC progression as any CAC increase over follow-up (including prevalent CAC in 2000-2001) and estimated relative rates of 10-year CAC progression with respect to TMAO using Poisson regression.
We assessed the sensitivity of results to the specification of TMAO in regression models. In addition to our primary analysis of sample-based quartiles, we included linear and quadratic specifications of continuous TMAO, and TMAO categories with cutpoints from a previous study of TMAO and CVD (<2.43, 2.43-3.66, 3.67-6.18, and >6.18 lmol/L). 2 We additionally considered prospective associations between TMAO and 10-year incidence of nonfatal CVD events using Cox proportional hazards regression, association between TMAO in 2000-2001 and level of common cIMT in 2005-2006 using linear regression, and the prospective association between TMAO and 10-year changes in eGFR and UACR using linear regression. We assessed potential selectivity of our study sample by comparing those eligible for our analysis (required to attend all 3 exams in the study period) and all participants who attended the 2000-2001 exam. Statistical analyses were completed with SAS (v9.4; SAS Institute Inc., Cary, NC) and Stata/MP (v14.0; StataCorp LP, College Station, TX) software.
Results
TMAO had an overall median (interquartile range; IQR) of 2.6 lmol/L (1.8-4.2), with medians of 1.3 lmol/L (IQR, 1.1, 1.5) in the lowest quartile and 6.6 lmol/L (5.1, 10.1) in the highest quartile (Table 1) . Quartile cutpoints of TMAO were <1.8, 1.8 to 2.5, 2.6 to 4.2, and >4.2 lmol/L, respectively. Across TMAO quartiles, there were significant differences in age, education, sex, HDL-C, triglycerides, and eGFR (Table 1) . TMAO was positively associated with egg consumption (P=0.02) and had a marginal positive association with red meat consumption (P=0.07), but was not associated with other dietary variables ( Table 2) .
CAC Incidence
Over the 10-year period, 184 individuals developed detectable CAC among those who were free of CAC at baseline (n=746). In multivariable-adjusted Poisson regression analysis, TMAO measured in 2000-2001 was not significantly associated with 10-year CAC incidence, among the 746 individuals free of CAC at baseline (rate ratio [RR]=1.03; 95% CI: 0.71-1.52, for the fourth vs first quartile; Table 3 ). These findings were not affected by adjustment for an extensive set of covariates, including CVD risk factors, kidney function, or egg and red meat consumption, or by alternative specifications of TMAO. In addition, further adjustment for blood pressure or lipidlowering medication use did not materially change findings (RR for CAC incidence=1.06; 95% CI: 0.72-1.55, comparing the fourth to the first quartile of TMAO).
We were limited in our ability to reliably examine associations according to higher levels of TMAO: 46% of our sample had a TMAO value that fell within the first quartile of TMAO concentration reported by Tang et Table 3 ). We tested other specifications of TMAO as well. Linear TMAO from a continuous specification was not statistically significantly associated with incident CAC (RR=1.01; 95% CI: 0.99-1.02). A quadratic TMAO specification also did not support an association between TMAO and CAC (data not shown). 
CAC Progression
In multivariable-adjusted Poisson regression analysis, TMAO was also not associated with CAC progression over the 10-year follow-up period (RR=0.97; 95% CI: 0.68-1.38, for the fourth vs first quartile; Table 5 ). TMAO was not associated with the 10-year incidence of nonfatal CVD events, although power for this analysis was low, with only 22 CVD events in our sample over the 10-year study period (data not shown). TMAO was also not associated with 10-year changes in eGFR or UACR (Table 6 ). In cross-sectional analysis (2000-2001), there was a suggestion of higher TMAO at lower eGFR, although few participants had low eGFR values (n=5 had eGFR <60 mL/min per 1.73 m 2 ) and differences were not statistically significant (data not shown). Individuals who were eligible for our study were somewhat healthier, as compared to those who were ineligible, as expected, given our requirements of survival and participation in the 3 CARDIA exams over the 10-year study period. However, CVD event rates were not appreciably different among those eligible and ineligible for our study. Furthermore, we note that a large percentage of participants had incident or progressive CAC over follow-up; in addition, measures predictive of CAC in previous work were significantly associated in our sample, including sICAM-1 20 and duration of adiposity 21 (data not shown).
Discussion
In a cohort of adults, aged 33 to 45, plasma TMAO concentration was not associated with CAC incidence or progression over 10 years of follow-up, after accounting for an extensive set of potential confounders. Nor was TMAO associated with other measures of CVD risk, including cIMT, insulin resistance, inflammatory markers, and lipids. TMAO concentrations in our sample were notably lower than in previous work that showed a positive association between TMAO and CVD risk. 2 Our results contribute to refining our understanding of population subgroups that may be most susceptible to the adverse effects of TMAO. In particular, our findings suggest that TMAO levels may not significantly influence progression of early atherosclerosis. Our results are not consistent with our hypothesis that TMAO is positively associated with CAC in an early-middle-age sample; however, our results are not necessarily inconsistent with previous reports that support a role for higher TMAO concentrations in advancing CVD risk in other groups. In a 2 These analytic approaches will not, however, compensate for meaningful differences between studies, most notably the younger age distribution and lower overall risk burden in our sample, if there are differential subgroup effects. For example, some studies show that TMAO may be most predictive of CVD among individuals with known comorbidities, including diabetes mellitus, 22 heart failure, [23] [24] [25] or chronic kidney disease, 26 though such results have been inconsistently reported. 27 High TMAO reflects higher consumption of TMAO precursors, some of which are also hypothesized to influence CVD risk. In the present analysis, statistical adjustment for dietary precursors, including red meat, eggs, and fish, did not materially impact effect estimates. The role of dietary precursors for TMAO in CVD risk is mixed, with red meat shown to increase CVD risk, whereas fish is considered cardioprotective. 28 In addition, recent data suggest that oral supplementation with TMAO precursor L-carnitine may contribute to lowering plasma lipoprotein(a). 29 We assessed the role of TMAO in advancing early atherosclerotic disease. One consideration is the relevance of studying a relatively young and healthy sample. However, this is a critical life period for primary prevention activities and 25% of our study sample developed detectable CAC over the 10-year study period. In addition, many studies have documented strong associations between risk factors measured from young adulthood to early middle age and CAC. For example, in previous CARDIA analysis, CAC at ages 33 to 55 has been associated with obesity, 21,30 F 2 -isoprostanes, 20 and nonoptimal lipids 31 measured in young adulthood or early middle age. Other studies have reported associations between traditional CVD risk factors and CAC measured at even younger ages. 32 We studied CAC because it is a strong predictor of future CVD events among asymptomatic individuals 8, 33 and because of compelling data that support an etiological role for TMAO in atherosclerosis. 1, 3, 4 In the apoE À/À mouse model, TMAO increased foam cell formation and accelerated progression of aortic plaque lesions. 1 Furthermore, in cross-sectional analysis of 1020 patients, there was a positive dose-response relationship between plasma TMAO and the number of coronary vessels (0-3) with ≥50% stenosis on diagnostic coronary angiography. 1 It is possible that our measures of atherosclerosis-CAC and carotid IMT-do not reflect TMAOrelated atherosclerotic processes. The precise mechanism through which TMAO may impact CVD risk remains under study, with reported data supporting potential effects on reverse cholesterol transport 3 and platelet activation. 34 More work is needed to determine the underlying mechanisms by which TMAO may affect disease risk, but published findings underscore the range of possible pathways through which TMAO may influence CVD risk. Still, our results were not expected, given that individuals with higher CAC scores have been shown to have greater total coronary plaque (calcified and noncalcified), 35 and calcification is associated with highrisk plaques and with acute coronary syndrome lesions. [36] [37] [38] A strength of our study was the ability to study the prospective association between TMAO and CAC in a relatively young and healthy population-based sample. We know of no other prospective study of TMAO and atherosclerosis in a population-based sample. Cross-sectional studies have yielded inconsistent support for an association between TMAO and atherosclerosis and have been limited by small samples or patient-based selection. 5, 25, [39] [40] [41] In addition, our study limited the potential for confounding by comorbidities, such as kidney function, an independent risk factor for CVD. 42 TMAO is excreted in urine, 43, 44 and circulating TMAO increases as kidney function declines. 45 The consideration that circulating TMAO may reflect kidney function, however, does not refute the possibility that high TMAO concentrations may adversely affect cardiovascular health, if, for example, TMAO influences atherosclerosis through a pathway related to declining kidney function. In C57BL/6J male mice, administration of TMAO promoted renal fibrosis and dysfunction. 26 Among 1434 Framingham Offspring Study participants, TMAO was 1 of 16 metabolites identified to be positively associated with incident chronic kidney disease (n=123 cases) over 8 years of follow-up. 46 We found some evidence that TMAO was associated with decreased kidney function in our analysis, though findings were not statistically significant. Additional strengths of the CARDIA study include extensive covariate data on traditional CVD risk factors, diet, kidney function, and inflammatory markers. In addition, our study captured a period of significant CAC progression-the prevalence of individuals with any CAC increased from 9% to 30% over the 10-year follow-up-and an important period for CVD prevention activities.
Along with the relative youth of our sample, eligibility criteria for our study selected for a generally healthy sample. Specifically, our requirement that individuals have all 3 CAC measurements eliminated participants who died or were lost to follow-up over the 10-year study period. However, as noted, CVD event rates were not appreciably different among those eligible and ineligible for our study, and significant associations have been found in previous studies of incident CAC with this same sample restriction.
Our study was not powered for the analysis of CVD events or subgroup differences, though, importantly, we had sufficient power to replicate previously reported associations between risk factors and CAC progression in the full CARDIA sample. 20, 21 Our analysis relied on analysis of TMAO from plasma that had been stored at À70°C from the time of fasting blood collection at the 2000-2001 exam. TMAO has been shown to be stable when stored at À80°C over 5 years, despite multiple freeze-thaw cycles, 47 but we know of no data on the stability of TMAO over 15 years. TMAO concentrations (median=2.6 lmol/L [IQR, 1.8-4.2]) in our sample were comparable to age-matched levels in a community-based sample (n=349) of healthy individuals. 47 In conclusion, in this population-based sample of earlymiddle-aged adults, plasma TMAO was not associated with eGFR indicates estimated glomerular filtration rate; TMAO, for trimethylamine N-oxide; UACR, urine albumin/creatinine ratio. *Regression models adjusted for age, sex, race, study center, educational attainment, current smoking status, physical activity, and body mass index. All covariates measured in 2000-2001.
10-year CAC incidence or progression or cIMT. Our results support the need for further research to define the role of TMAO in CVD-related outcomes across the distribution of circulating TMAO concentrations and among population groups with variable underlying CVD risk or risk factors such as diet or gut microbiota.
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